Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Zilbrysq Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Zilbrysq Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Zilbrysq (zilucoplan) subcutaneous prefilled syringes for commercial plan members. It establishes initial and renewal clinical criteria, nonpreferred-agent requirements, prohibited combination therapy, contraindication screening, and dispensing limits.

    Policy Summary
    PayerPrime Therapeutics
    PolicyZilbrysq Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 15, 2025
    Next Review DateN/A
    Key ActionSubmit documentation supporting the diagnosis, MGFA clinical class, MG-ADL score, medication assessment, treatment history, and applicable preferred-agent history.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsInitial authorization
    12 monthsRenewal authorization
    28 syringesQuantity limit
    Anti-AChR positiveRequired serology

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥6Required MG-ADL score

    Coverage Criteria

    Initial Therapy

    Target Agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • A. The patient has a diagnosis of generalized Myasthenia Gravis (gMG)

        • The patient has a positive serological test for anti-AChR antibodies.

          Medical records required.

        • The patient has a Myasthenia Gravis Foundation of America (MGFA) clinical classification of class II-IVb.
        • The patient has a MG-Activities of Daily Living total score of greater than or equal to 6.>= 6
        • ONE of the following

          • The patient's current medications have been assessed and any medications known to exacerbate myasthenia gravis (e.g., beta blockers, procainamide, quinidine, magnesium, anti-programmed death receptor-1 monoclonal antibodies, hydroxychloroquine, or aminoglycosides) have been discontinued.
          • Discontinuation of the offending agent is not clinically appropriate.
        • ONE of the following

          • The patient has tried and had an inadequate response to at least ONE conventional agent used for the treatment of myasthenia gravis (i.e., corticosteroids, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, or cyclophosphamide).
          • The patient has an intolerance or hypersensitivity to ONE conventional agent used for the treatment of myasthenia gravis (i.e., corticosteroids, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, or cyclophosphamide).
          • The patient has an FDA-labeled contraindication to ALL conventional agents used for the treatment of myasthenia gravis (i.e., corticosteroids, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, or cyclophosphamide).
          • The patient required chronic intravenous immunoglobulin (IVIG).
          • The patient required chronic plasmapheresis/plasma exchange.
        • If the client has preferred agent(s), ONE of the following

          • The patient has tried and had an inadequate response to ONE preferred agent.
          • The patient has an intolerance or hypersensitivity to ONE preferred agent.
          • The patient has an FDA-labeled contraindication to ALL preferred agent(s).
      • The patient has another FDA-labeled indication for the requested agent and route of administration.
    • If the patient has an FDA-approved indication, ONE of the following

      • The patient's age is within FDA labeling for the requested indication for the requested agent.
      • There is support for using the requested agent for the patient's age for the requested indication.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient will NOT be using the requested agent in combination with Rystiggo (rozanolixizumab-noli), Soliris (eculizumab), Bkemv (eculizumab-aeeb), Epysqli (eculizumab-aagh), Ultomiris (ravulizumab-cwvz), Vyvgart (efgartigimod), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), or Imaavy (nipocalimab-aahu).
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Continuation Therapy

    Target Agent(s) will be approved for renewal when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent will require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient will NOT be using the requested agent in combination with Rystiggo (rozanolixizumab-noli), Soliris (eculizumab), Bkemv (eculizumab-aeeb), Epysqli (eculizumab-aagh), Ultomiris (ravulizumab-cwvz), Vyvgart (efgartigimod), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), or Imaavy (nipocalimab-aahu).

    Quantity-Limit Exception

    Quantity limit for the Target Agent(s) will be approved when ONE of the following is met:

    ONE of the following

    • The requested quantity (dose) does NOT exceed the program quantity limit.
    • The requested quantity (dose) exceeds the program quantity limit AND ONE qualifying exception pathway is met

      • ONE qualifying exception pathway

        • Pathway A

          • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.
          • There is support for therapy with a higher dose for the requested indication.
        • Pathway B

    The patient will NOT be using the requested agent in combination with Rystiggo (rozanolixizumab-noli), Soliris (eculizumab), Bkemv (eculizumab-aeeb), Epysqli (eculizumab-aagh), Ultomiris (ravulizumab-cwvz), Vyvgart (efgartigimod), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), or Imaavy (nipocalimab-aahu).

    Coding and Quantity Parameters

    MG-ADL threshold
    MeasureMyasthenia Gravis Activities of Daily Living (MG-ADL) total score
    Required thresholdGreater than or equal to 6
    Applicable pathwayGeneralized myasthenia gravis
    MGFA clinical classification
    ClassificationMyasthenia Gravis Foundation of America (MGFA) clinical classification
    Qualifying rangeClass II-IVb
    Applicable pathwayGeneralized myasthenia gravis

    Provider Requirements and Approval Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the non-preferred target agent Zilbrysq (zilucoplan). Approval requires the applicable FDA-labeled indication and clinical criteria documented in the medical record.

    • Preferred agents may be targeted through another utilization management program and may require separate prior authorization.
    • For generalized myasthenia gravis, document the required diagnosis, serology, disease severity, medication assessment, conventional-therapy history, and preferred-agent requirements.
    • If the requested agent is being used for another FDA-approved indication, document the indication, route of administration, and applicable age criteria or clinical support.
    Note

    Authorization Duration

    Authorization periods depend on the review stage. Initial approval is limited to 3 months, while renewal approval is issued for 12 months when renewal criteria are met.

    • Initial authorization: 3 months.

    Policy Background

    Zilbrysq (zilucoplan) is evaluated primarily for patients with generalized myasthenia gravis through a prior authorization program. The principal clinical pathway requires positive anti-acetylcholine receptor antibodies, MGFA class II-IVb disease, and an MG-ADL score of at least 6, along with prior conventional-treatment experience or a qualifying exception.

    Clinical Definitions

    MGFA class II-IVb
    Classification systemMyasthenia Gravis Foundation of America clinical classification
    Qualifying classesClass II-IVb
    Clinical useDefines the qualifying disease severity range for the generalized myasthenia gravis pathway
    MG-ADL score
    MeasureMyasthenia Gravis Activities of Daily Living total score
    ThresholdGreater than or equal to 6
    Clinical useRequired for the generalized myasthenia gravis pathway

    Initial Zilbrysq Approval

    Zilbrysq Initial Approval

    Initial Zilbrysq approval requires ALL applicable criteria.

    Zilbrysq initial approval

    • Qualifying indication

      • Generalized myasthenia gravis

        • The patient has generalized myasthenia gravis with a positive serological test for anti-AChR antibodies, MGFA clinical classification class II-IVb, and an MG-ADL total score of at least 6.Anti-AChR positive; MGFA class II-IVb; MG-ADL ≥6

          Medical records documenting the positive serological test are required.

        • Medication assessment

          • The patient's current medications have been assessed and medications known to exacerbate myasthenia gravis have been discontinued.

    Zilbrysq Renewal

    Zilbrysq Renewal

    Renewal of Zilbrysq requires ALL of the following.

    Zilbrysq renewal

    • The patient was previously approved for Zilbrysq through the plan's Prior Authorization process.

      Patients not previously approved require initial evaluation review.

    • The patient has had clinical benefit with Zilbrysq.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as a neurologist, or has consulted with a specialist in that area.
    • The patient will not use Zilbrysq in combination with Rystiggo, Soliris, Bkemv, Epysqli, Ultomiris, Vyvgart, Vyvgart Hytrulo, or Imaavy.

    Step-Therapy Requirements

    StepRequirementQualifying exceptions
    1If the client has preferred agent(s), the patient must try and have an inadequate response to one preferred agent.Intolerance or hypersensitivity to one preferred agent, or an FDA-labeled contraindication to all preferred agents.
    StepRequirementQualifying exceptions
    2The patient must try and have an inadequate response to at least one conventional agent used to treat myasthenia gravis.Intolerance or hypersensitivity to one conventional agent; an FDA-labeled contraindication to all conventional agents; chronic intravenous immunoglobulin (IVIG); or chronic plasmapheresis/plasma exchange.

    Zilbrysq Quantity Limits

    Zilbrysq 16.6 mg/0.416 mL
    Strength16.6 mg/0.416 mL
    Quantity limit28 syringes
    Limit periodPer 28 days
    Zilbrysq 23 mg/0.574 mL
    Strength23 mg/0.574 mL
    Quantity limit28 syringes
    Limit periodPer 28 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyZilbrysq Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 15, 2025
    Next Review DateN/A
    Key ActionSubmit documentation supporting the diagnosis, MGFA clinical class, MG-ADL score, medication assessment, treatment history, and applicable preferred-agent history.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Quantity ParametersProvider Requirements and Approval RisksPolicy BackgroundClinical DefinitionsInitial Zilbrysq ApprovalZilbrysq RenewalStep-Therapy RequirementsZilbrysq Quantity Limits
    The patient does NOT have any FDA-labeled contraindications to the requested agent.
  1. The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication.
  2. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit.
  3. Pathway C

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
    • There is support for therapy with a higher dose for the requested indication.
  4. Quantity limit
    Quantity limit28 syringes
    Time periodPer 28 days
    Applies toZilbrysq target agent strengths
  5. Renewal authorization: 12 months.
  6. If a quantity limit applies, the separate quantity-limit criteria must also be satisfied.
  7. Step Therapy

    Conventional Myasthenia Gravis Therapy

    For generalized myasthenia gravis, document prior conventional therapy or a qualifying exception before requesting the target agent.

    • Inadequate response to at least one conventional agent: corticosteroids, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, or cyclophosphamide.
    • Intolerance or hypersensitivity to at least one conventional agent.
    • FDA-labeled contraindication to all listed conventional agents.
    • Chronic IVIG or chronic plasmapheresis/plasma exchange.
    Step Therapy

    Preferred-Agent Requirement

    When preferred agent(s) are available, document that the patient tried and had an inadequate response to one preferred agent, or document a qualifying exception.

    • Intolerance or hypersensitivity to one preferred agent.
    • FDA-labeled contraindication to all preferred agents.
    • A preferred-agent trial or exception is not required when the patient has another FDA-labeled indication for the requested agent and route of administration.
    Documentation Required

    Anti-AChR Serology

    Submit medical records documenting a positive serological test for anti-acetylcholine receptor (anti-AChR) antibodies for a generalized myasthenia gravis request.

    • Positive anti-AChR antibody testing is required.
    • Medical records supporting the test result are required.
    Documentation Required

    Clinical Evaluation Records

    Provide clinical evaluation records supporting the diagnosis, severity, medication assessment, and treatment history for generalized myasthenia gravis.

    • Diagnosis of generalized myasthenia gravis.
    • Myasthenia Gravis Foundation of America (MGFA) clinical classification class II-IVb.
    • MG-Activities of Daily Living (MG-ADL) total score ≥6.
    • Current medications assessed, including documentation that medications known to exacerbate myasthenia gravis were discontinued or that discontinuation is not clinically appropriate.
    • Treatment history, including conventional-agent response or qualifying exception and any chronic IVIG or plasmapheresis/plasma exchange.
    Documentation Required

    Renewal Documentation

    Renewal requests require documentation that the patient was previously approved through the plan's prior authorization process and continues to benefit from therapy.

    • Document prior approval; patients without prior approval require initial evaluation.
    • Document clinical benefit with the requested agent.
    • The prescriber must be a specialist in the diagnosis area, such as a neurologist, or must have consulted with one.
    • Confirm the requested agent will not be used with prohibited combination therapies.
    • Confirm the patient has no FDA-labeled contraindication to the requested agent.
    Denial Risk

    Clinical Criteria Not Met

    Requests are at risk for denial when the required indication or generalized myasthenia gravis criteria are not established.

    • For generalized myasthenia gravis, required documentation includes positive anti-AChR antibodies, MGFA class II-IVb, MG-ADL score ≥6, medication assessment, and conventional-therapy history or a qualifying exception.
    • Requests may be denied when the diagnosis, FDA-approved indication, age/route criteria, or required clinical support is not documented.
    • Requests may be denied when applicable preferred-agent requirements are not met.
    Denial Risk

    Prohibited Combination Therapy

    Do not use the requested agent in combination with specified complement, neonatal Fc receptor, or related therapies; such combination therapy may result in denial.

    • Rystiggo (rozanolixizumab-noli)
    • Soliris (eculizumab), Bkemv (eculizumab-aeeb), or Epysqli (eculizumab-aagh)
    • Ultomiris (ravulizumab-cwvz)
    • Vyvgart (efgartigimod) or Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)
    • Imaavy (nipocalimab-aahu)
    Denial Risk

    FDA-Labeled Contraindication

    Approval may be denied when the patient has an FDA-labeled contraindication to the requested agent.

    • Document review of the current FDA-labeled contraindications for the requested product.
    • The absence of applicable contraindications must be confirmed for both initial and renewal requests.
    Denial Risk

    Quantity-Limit Exception

    A quantity exceeding the program limit requires additional clinical support; unsupported quantity-limit exceptions may be denied.

    • The requested dose does not exceed the program quantity limit; or
    • The agent has no maximum FDA-labeled dose for the indication and support is provided for the higher dose; or
    • The dose does not exceed the maximum FDA-labeled dose and documentation explains why it cannot be achieved with a lower quantity of a higher strength within the program limit; or
    • The requested dose exceeds the maximum FDA-labeled dose and support is provided for therapy with the higher dose.
    • Quantity-limit authorization period: initial 3 months; renewal 12 months.
    Anti-AChR antibody test
    TestAnti-acetylcholine receptor antibody serologic testing
    Required resultPositive serological test for anti-AChR antibodies
    DocumentationMedical records are required
  8. Discontinuation of the offending medication is not clinically appropriate.
  9. Conventional-treatment qualification

    • The patient tried and had an inadequate response to at least one conventional agent used to treat myasthenia gravis.
    • The patient has an intolerance or hypersensitivity to one conventional agent used to treat myasthenia gravis.
    • The patient has an FDA-labeled contraindication to all conventional agents used to treat myasthenia gravis.
    • The patient required chronic IVIG.
    • The patient required chronic plasmapheresis or plasma exchange.
  10. Other FDA-labeled indication: The patient has another FDA-labeled indication for Zilbrysq and the requested route of administration.
  11. Preferred-agent requirement when applicable: If the client has preferred agents, the patient tried and had an inadequate response to one preferred agent, had an intolerance or hypersensitivity to one preferred agent, or has an FDA-labeled contraindication to all preferred agents.
  12. Age requirement

    • The patient's age is within FDA labeling for the requested indication.
    • There is support for using Zilbrysq for the patient's age and requested indication.
  13. Prescriber qualification: The prescriber is a specialist in the area of the patient's diagnosis, such as a neurologist, or has consulted with a specialist.
  14. Safety and combination restrictions: The patient will not use Zilbrysq in combination with Rystiggo, Soliris, Bkemv, Epysqli, Ultomiris, Vyvgart, Vyvgart Hytrulo, or Imaavy, and the patient does not have an FDA-labeled contraindication to Zilbrysq.
  15. The patient does not have an FDA-labeled contraindication to Zilbrysq.
    Zilbrysq 32.4 mg/0.81 mL
    Strength32.4 mg/0.81 mL
    Quantity limit28 syringes
    Limit periodPer 28 days